DFTX or CMPS: Trump's Psychedelic Therapy Stock Winner?
April 20, 2026·about 2 hours ago·via Stocktwits
Investors eye DFTX vs. CMPS as Trump's push for psychedelic therapy unlocks massive upside in innovative healthcare. Ditching Big Pharma's pill-pushing monopoly, this America First initiative champions cutting-edge treatments for veterans' PTSD and mental health without government red tape. Free markets thrive under Trump, rewarding bold companies solving real problems. Skeptical of FDA overreach, patriots back therapies that empower individuals over bureaucratic bans. Which stock surges? Read more about this...